Salix Investor Challenges $2.7B Inversion Deal With Cosmo
A Salix Pharmaceuticals Ltd. investor launched a putative class action Tuesday claiming Salix's proposed $2.7 billion merger with the Irish operations of Cosmo Pharmaceuticals SpA will allow the company to seek...To view the full article, register now.
Already a subscriber? Click here to view full article